Garadacimab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
Garadacimab: clinical details
Prescribing considerations
- Initiate under a physician experienced in HAE management.
- Do not use to treat acute HAE attacks; retain an individualised rescue plan.
- Clinical evidence in HAE with normal C1-inhibitor activity is very limited, and response may depend on the underlying pathway; consider appropriate genetic characterisation and review effectiveness.
- Safety and efficacy have not been established below 12 years.
- The product is under additional monitoring; report suspected adverse reactions through the Yellow Card Scheme.
- Be aware of proline in patients with hyperprolinaemia and polysorbate 80 in patients with relevant allergy.
Contraindications and cautions
- Hypersensitivity to garadacimab or any excipient.
Monitoring
- Review attack frequency and overall clinical response.
- Observe for hypersensitivity and stop treatment if a severe reaction occurs.
- Record the product name and batch number for biological-medicine traceability.
- Tell the laboratory that the patient receives garadacimab: it can prolong aPTT through assay interference without indicating abnormal bleeding.
- Interpret D-dimer cautiously because treatment may lower results.
- Use particular caution when interpreting haemostasis in patients with coagulopathy or concurrent anticoagulant or antiplatelet treatment, where evidence is limited.
Clinical pharmacology
A recombinant fully human IgG4/lambda monoclonal antibody that binds the catalytic domain of FXIIa and βFXIIa. Inhibiting activated factor XII reduces kallikrein-pathway activation and bradykinin generation.
Formulation and product differences
- Ready-to-use solution in a single-use pre-filled pen for subcutaneous injection.
- The solution should be slightly opalescent to clear and brownish-yellow to yellow; do not shake or use it if discoloured or particulate.
- Store refrigerated and protected from light. Limited room-temperature storage is permitted under the product instructions, after which it must not be returned to the refrigerator.
Garadacimab preparations and strengths
Injection
Route: Parenteral
Strengths: 200 mg
Garadacimab interactions
No established direct medicine interactions are listed, but dedicated human interaction studies are limited.
Anticoagulants and antiplatelet medicines
Experience with combined use is very limited, and the clinical effect of combining garadacimab with some anticoagulants is unknown.
Other long-term preventive HAE treatments
Garadacimab has not been studied in combination with other products used for long-term HAE prevention.
C1-esterase inhibitor products or icatibant
Use as rescue treatment for breakthrough attacks did not affect garadacimab pharmacokinetics in available analyses.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.